Focused On-demand Library for Protein bicaudal D homolog 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8TD16

UPID:

BICD2_HUMAN

Alternative names:

Alternative UPACC:

Q8TD16; O75181; Q5TBQ2; Q5TBQ3; Q96LH2; Q9BT84; Q9H561

Background:

Protein bicaudal D homolog 2 plays a pivotal role in cellular dynamics, acting as an essential adapter that links the dynein motor complex to various cargos. It enhances dynein's processivity and facilitates the interaction between dynein and dynactin. Moreover, it plays a crucial role in cellular transport mechanisms, including Golgi-ER transport, through its interaction with RAB6A and the dynein-dynactin motor complex. Its involvement in nuclear and centrosomal positioning underscores its importance in cell cycle progression.

Therapeutic significance:

Given its critical functions in cellular transport and cell cycle regulation, Protein bicaudal D homolog 2 is implicated in severe diseases such as Spinal muscular atrophy, types 2A and 2B. These conditions underscore the protein's potential as a target for therapeutic intervention, offering hope for treatments that could ameliorate or even cure these debilitating diseases.